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Abstract
Background:  Expression of P-glycoprotein (P-gp), the multidrug resistance (MDR) 1 gene
product, can lead to multidrug resistance in tumours. However, the physiological role of P-gp in
tumours growing as multicellular spheroids is not well understood. Recent evidence suggests that
P-gp activity may be modulated by cellular components such as membrane proteins, membrane-
anchoring proteins or membrane-lipid composition. Since, multicellular spheroids studies have
evidenced alterations in numerous cellular components, including those related to the plasma
membrane function, result plausible that some of these changes might modulate P-gp function and
be responsible for the acquisition of multicellular drug resistance. In the present study, we asked if
a human lung cancer cell line (INER-51) grown as multicellular spheroids can modify the P-gp
activity to decrease the levels of doxorubicin (DXR) retained and increase their drug resistance.
Results: Our results showed that INER-51 spheroids retain 3-folds lower doxorubicin than the
same cells as monolayers however; differences in retention were not observed when the P-gp
substrate Rho-123 was used. Interestingly, neither the use of the P-gp-modulating agent
cyclosporin-A (Cs-A) nor a decrease in ATP-pools were able to increase DXR retention in the
multicellular spheroids. Only the lack of P-gp expression throughout the pharmacological selection
of a P-gp negative (P-gpneg) mutant clone (PSC-1) derived from INER-51 cells, allow increase of
DXR retention in spheroids.
Conclusion: Thus, multicellular arrangement appears to alter the P-gp activity to maintain lower
levels of DXR. However, the non expression of P-gp by cells forming multicellular spheroids has
only a minor impact in the resistance to chemotherapeutic agents.
Background
Multidrug resistance to chemotherapy is one of the biggest
problems in the treatment of cancer. Currently, the best
understood mechanism of multidrug resistance (MDR) is
associated with the overexpression of protein efflux-pump
known as P-glycoprotein (P-gp), but other non-Ppg mech-
anisms are also involved (i.e. MRP1, topoisomerases, glu-
tathione-S transferases, etc). The P-gp is the protein
product of the MDR-1 gene and is expressed as a trans-
membranal protein (Mr 170 000) capable of decreasing
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the intracellular concentration of a broad range of cyto-
toxic agents in an energy-dependant mediated efflux [1,2].
Overexpression of P-gp in human cell lines confers resist-
ance to many of the most effective chemotherapeutic
agents used clinically in chemotherapy, including anthra-
cyclines (e.g., doxorubicin (DXR)), Vinca alkaloids (e.g.,
vincristine), epipodophyllotoxins (e.g., etoposide), actin-
omycin D, paclitaxel, as well as many others non-chemo-
therapeutic agents like Rhodamine-123 and ethidium
bromide [3]. Although the more accepted model is that
the P-gp by itself extrude chemotherapeutic agents out of
the cells, more recent studies suggest that P-gp activity
may be modulated by cellular components such as mem-
brane proteins, membrane-anchoring proteins or the
composition of lipids themselves [4-7].
Since the first studies by Sutherland et al in 1979 [8], it
was shown that tumour cells growing as multicellular
spheroids resembles many of the behaviours found in
solid tumours, including multicellular resistance (MCR)
[9,10]. Using the model of multicellular spheroids, sev-
eral authors have shown that P-gp, is more efficient to
conferring resistance in cells cultivated as spheroids as
compared to cells cultivated as monolayers [11-13]. From
these observations, one question arises: Can tumour cells
modulate its P-gp activity as a direct consequence of the
environmental condition where grown? To address this
question, we studied an NSCLC cell line named INER-51
that showed a P-gp-mediated resistance to DXR in the
spheroid model. In early studies with INER-51 cells, we
found that the formation of multicellular spheroids does
not show any increase in mRNA for MDR-1 gene or in a
differential P-gp expression in the specific areas of the
spherule.
Results
Doxorubicin and Rhodamine-123 retention in spheroids
It is well known that multicellular spheroids are more
resistant to chemotherapeutic drugs than the same cell
cultures as monolayers [11,12]. With the aim to evaluate
differences in P-gp activity in multicellular spheroids with
respect to monolayers, two P-gp substrates were used
(DXR and Rho-123). Both compounds were chosen,
because they are good P-gp substrates with an autofluores-
cence capacity. Our results showed that in monolayers the
amount of DXR retained in the cells was in direct propor-
tion to the drug added to the medium (Figure 1). In con-
trast, multicellular spheroids showed a lower capacity for
DXR retention (3-fold lower) than monolayers. Interest-
ingly, this poor retention was not observed when Rho-123
was used as P-gp substrate because the Rho-123 levels
retained were equal in both types of cultures (box insert
in Figure 1a).
Since the drug-retention is a dynamic process that
involves drug uptake (simple diffusion) as well as drug
linkage (diffusion vs. expulsion mediated for an active
mechanism), we tried to determine whether a more effi-
cient P-gp-dependent drug removal was responsible for
allowing lower intracellular DXR concentrations. Thus,
drug-removal in monolayers previously loaded with 30
µM of DXR during 30 min showed a first order decay reac-
tion with a half-time of drug concentration at the first 5
minutes interval that indicated the presence of an active
transport mechanism (Figure 1b). However, for multicel-
lular spheroids the presence of active transport was not
evident since its was not possible to load the cells with suf-
ficient amounts of DXR to determine the efflux values. A
common observation in these experiments was that a con-
stant amount of DXR was retained for a longer period of
time (45 minutes) in cells grown as monolayers. A possi-
ble explanation could be from the presence of positively
charged-DXR, which stores in acidic vesicles as chromaffin
granules and lysosomes [20,21].
Circumvention of DXR retention with P-pg reversal agents
With the aim to determine how much the P-gp influences
the levels of DXR retained, the modulator agent Cs-A was
employed. As shown in the Figure 2, the incubation of
monolayers with 5 µM of Cs-A efficiently enhances (2-
fold) the intracellular DXR fluorescence in direct relation
to reversal agent concentration. Surprisingly, the P-gp-
modulation activity of Cs-A was not evident in multicellu-
lar spheroids because no effect in the intracellular DXR
retention could be seen. Also, other reversal agents, like
SDZ PSC 833 and verapamil were not able to increase
DXR retention, neither in monolayers nor in multicellular
spheroids (data not shown).
Effect of ATP-depletion in DXR retention
P-gp is a protein that belongs to the ABC binding cassette
protein, for which efficient drug efflux needs ATP hydrol-
ysis. Thus, with the propose to achieve more information
about the P-gp function, we decided to inhibit the P-gp
activity through depletion of ATP-pools. Three metabolic
poisons were used to be sure of complete ATP-depletion
in multicellular spheroids. Figure 3 shows that ATP-deple-
tion did induce a 1.5-fold increase of DXR retention in
cells maintained as monolayers but none effect was again
seen when in ATP-depleted multicellular spheroids.
Achieving the PSC-1 mutant clone non-expressing P-gp
With no possibility of obtaining irrefutable evidence of P-
gp modulation from multicellular spheroids, we decided
to eliminate the P-gp expression from the lung cancer line.
Therefore, through the co-selection of the parental cell
line INER-51 with 5 µM of DXR and 5 µM of SDZ PSC
833, we were able to obtain one mutant cell clone that did
not express P-gp, which was named PSC-1 line (FigureCancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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Dose-dependence of doxorubicin-retention in INER-51 cells Figure 1
Dose-dependence of doxorubicin-retention in INER-51 cells. (a) Tumour cells growth as monolayers (filled circles) or multicel-
lular spheroids (open circles) were incubated with increased concentrations of DXR or Rho-123 (Insert box) for 30 min and then 
intracellular fluorescence was determinated by spectrofluormetry. b) Time-course of DXR efflux in INER-51 cells. Monolayers 
(filled circles) and a multicellular spheroids (open circles) were previously loaded with 30 µM of DXR for 30 min and afterwards 
the remaining DXR was quantitated in several intervals of time. Each point represents the mean of at least 3 experiments and 
error bars are the standard error of the mean.Cancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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4a). In vitro RT-PCR analysis of other MDR-related genes
did not show qualitative differences between parent and
mutant cells (Figure 4b). The amplification experiments
showed that both cells lines express with approximately
with the same intensity transcripts for topoisomerase I,
topoisomerase IIα and topoisomerase IIβ but neither of
them expressed the multidrug resistance-associated pro-
tein (MRP1) or glutathione-S transferase-µ.
DXR retention and drug cytotoxicity in PSC-1 cells
The similarities between INER-51 cells (P-gppos) and PSC-
1 cells (P-gpneg), allowed us the possibility to evaluate
whether or not the lower DXR-retention levels were medi-
ated by a positively modulated P-gp-mechanism. The
incubation of PSC-1 spheroids with increasing DXR con-
centrations showed a significative increase in the drug
retention (1.8-fold) in comparison to INER-51 spheroids
and was only 1.6-fold lower than PSC-1 growth as monol-
ayers (Figure 5). When Rho-123 was assayed, an increase
in the retention of the dye relative to the parental line
INER-51 as monolayers was evident. In PSC-1 spheroids,
the levels of Rho-123 retention were similar in both INER-
51 monolayers and multicellular spheroids (box insert in
Figure 5).
Circumvention of doxorubicin-retention by cyclosporin-A (Cs-A) Figure 2
Circumvention of doxorubicin-retention by cyclosporin-A (Cs-A). INER-51 cells growth as monolayers (filled circles) or multi-
cellular spheroids (open circles) were treated with increase concentrations of Cs-A for 1 hour previous to being loaded with 30 
µM of DXR for 30 min in presence of reversal agent. Doxorubicin retained was determinate by spectrofluormetry. Each point 
represents the mean of at least 3 experiments and the error bars are the standard error of the mean.Cancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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Several techniques have been used to evaluate the MCR in
multicellular spheroids. Since in previous experiments we
were unable to successfully disaggregate multicellular
spheroids through trypsin-based protocols, we decided to
evaluate the MCR using the MTT assay (which as been pre-
viously evaluated by Furukawa et al[17]. Interestingly, this
assay showed that the increase in DXR retention had only
a minor impact in the MCR. Thus, PSC-1 spheroids were
able to maintain their resistance to DXR or etoposide as
the parental INER-51 cells (Figure 6a,b) with only minor
changes in the IC50 values (Table 1). Only when PCS-1
cells were assayed against the cytotoxic effect of meth-
otrexate (which use another detoxification via previous to
P-gp), differences between INER-51 cells and PSC-1 cells
could be seen (Figure 6c).
Discussion
It is well known that the three-dimensional arrangement
evoke deeper structural changes in the cells to maintain
the integrity of the multicellular structure, some of which
Effect of ATP-depletion in doxorubicin-retention Figure 3
Effect of ATP-depletion in doxorubicin-retention. INER-51 cells as monolayers or multicellular spheroids were pre-incubated 
(open symbols) or not (filled symbols) with 1 mM sodium-cyanide, 10 mM sodium-fluoride, 10 mM sodium azide before the addi-
tion of increased DXR concentrations. The intracellular DXR-fluorescence was evaluated by spectrofluormetry. Each point 
represents the mean of at least 3 experiments and the error bars are the standard error of the mean. The Student's t-test for 
paired data was performed to identify changes in DXR retention. The results were considered to be significant when p < 0.05. 
NS: no significant.Cancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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include: a) the expression of proteins of ECM [22]; b)
membrane protein anchoring [23,24]; c) heat shock
proteins [25] and d) adhesion proteins as well as changes
in lipid membrane composition and hypoxia [26-29].
Another phenomenon frequently observed in tumour
cells growing as multicellular spheroids is the acquisition
of MCR. In spheroids cultures as well in monolayer sys-
tems one of the major mechanisms to confer resistance is
shown by the expression of P-gp. However, some evidence
suggests that to confer MCR, the P-gp also seems to work
more efficiently [11,12]. Recent data suggests that P-gp
activity can be modulated through the interaction with
diverse cellular components, some of which are also
altered when cells are multicellular spheroids [4-7,11,12].
Thus, it would be interesting to know if to acquire MCR,
tumour cells spheroids can modulate its P-gp activity.
Our findings suggest that a more efficient P-gp-mediated
efflux seems to be responsible for maintaining lower lev-
els of DXR in INER-51 spheroids than cells in monolayer
cultures. However, this P-gp mediated drug efflux did not
seem to operate under the same conditions with others
RT-PCR analysis of the levels of expression for MDR genes in the parental cell line INER-51 as well as the PSC-1 cell clone Figure 4
RT-PCR analysis of the levels of expression for MDR genes in the parental cell line INER-51 as well as the PSC-1 cell clone. a) 
Amplification of MDR-1 gene visualized by ethidium bromide (left) or autoradiagraph (middle). The expression of G3PDH gene 
was used as a constitutive control for the integrity of the RNA molecules. b) Amplification by RT-PCR of other non-MDR-1 
genes related to MDR phenotype. As control (CTL) of gene expression, the next cell lines and tissues were used: INER-37 cell 
line for MRP1 and GST-µ; A427 cell line for MDR-1; HeLa cell line for topoisomerase I, topoisomerase IIα and topoisomerase 
IIβ; finally, placental tissue was used as a control of BCRP expression.Cancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
Page 7 of 13
(page number not for citation purposes)
substrates, because when the lipophilic cation Rho-123
was used, the levels of retention were similar and inde-
pendent of the culture conditions.
Under the spheroid condition, P-gp appears to obey dif-
ferent regulatory mechanisms since neither Cs-A treat-
ment nor ATP-depletion were able to increase the levels of
DXR into the spherules. Other non-P-gp mediated mech-
anisms also appear to be operating to maintain lower
DXR levels in the multicellular spheroids, because the lack
of P-gp expression did not reach levels of DXR compara-
ble to the monolayer's cultures and had only a minor
impact in the acquisition of MCR to chemotherapeutic
agents, including DXR.
Some evidences has shown that the membrane-cell com-
position can modulate the transbilayer movement rate of
MDR-type drugs across the membrane and consequently
affects the "competition" between the active P-gp-medi-
ated drug efflux and the passive drug uptake: i.e. retention
Comparative doxorubicin retention of PSC-1 cells and INER-51 cells Figure 5
Comparative doxorubicin retention of PSC-1 cells and INER-51 cells. PSC-1 tumour cells growth as monolayers (filled circles) 
or multicellular spheroids (filled triangles) and INER-51 monolayers (open circles) or multicellular spheroids (open triangles) were 
incubated with increased concentrations of DXR (as in Figure 1) and then intracellular fluorescence was determined by spec-
trofluormetry. Insert box. Rhodamine-123-retention in PSC-1 cell growth as monolayers or multicellular spheroids.Cancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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Cytotoxicity of doxorubicin (a), etoposide (b) and methotrexate (c) in monolayers or multicellular spheroids from PSC-1 (P- gpneg) clone cells in comparison to the parental INER-51 cell line Figure 6
Cytotoxicity of doxorubicin (a), etoposide (b) and methotrexate (c) in monolayers or multicellular spheroids from PSC-1 (P-
gpneg) clone cells in comparison to the parental INER-51 cell line. Cytotoxicity was measurement by the MTT colorimetric 
assay and expressed as percent growth inhibition in comparison with the untreated tumour cells. Each point represents the 
mean of at least 3 independent experiments and error bars are the standard error of the meanCancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
Page 9 of 13
(page number not for citation purposes)
[30]. Particularly, DXR has shown to have a lower rate of
penetration through membranes due to its specific
interactions with cardiolipin [31,32]. Since membrane
changes affecting plasma membrane do not confer resist-
ance themselves but could drive the P-gp function [33-
35], we hypothesize a possible drawing to understand
how P-gp successfully maintains lower DXR concentra-
tions. In this picture, a delay in the rate of passive transbi-
layer movement of DXR through the plasma membrane
results in an enhanced ability of P-gp to recognize and
extrude it out of the spheroids. Thus, when P-gp is absent
(as in PSC-1 cells), the saturation of lipid targets permit
the increase of the DXR concentration into the multicellu-
lar spheroids. Enhanced efficiency of P-gp to extrude sub-
strates has been fully demonstrated by different members
of the DXR and rhodamine dry analogues, with each one
having different lipophilic properties [36].
Several studies have shown that the use of modulator
agents provoke the sensitisation of cell growth as multicel-
lular spheroids [37-39]. The efficacy of these agents is due
to the higher permeability rate in relation to P-gp
substrates [40]. However, when INER-51 spheroids were
pre-treated with 10 µM of the modulator agent of Cs-A, no
increase in DXR retention was observed. A similar phe-
nomenon was observed in multicellular spheroids treated
with verapamil [38,39]. Today, a number of studies using
various techniques have suggested a probable model of
interaction between P-gp-substrates with modulators
agents and how these molecules bind to different sites on
P-gp [41]. Four binding sites have been identified on P-gp
of which vinblastine and daunorubicin bind to the site I,
whereas modulators bind to site IV. In this model, all the
binding sites display allosteric interaction between each
one of them, thus affecting P-gp-mediated activity. In
addition, an unrecognised binding site has been proposed
for Rho-123 [42-44]. Thus, the failure of Cs-A to inhibit P-
gp-mediated DXR efflux may be a consequence of changes
in the P-gp affecting the modulator-binding site or the
allosteric inhibition with some hypothetic molecule.
Recently, in cells with MDR-phenotype, it has been dem-
onstrated that a specific interaction exists between P-gp
and HSP-90 [45]. If spherules formation elicits the expres-
sion of HSP-90, which is able to bind P-gp, the failure of
Cs-A inhibition might be understood. Furthermore, the
allosteric inhibition of the modulator site by unknown
factors could be an explanation for the common failure
seen when solid tumours, including lung cancer tumours,
are treated with reversal agents [46].
Another interesting observation came from the impact of
ATP depletion in DXR retention. For this experiment we
used a metabolic cocktail poison to be certain of the ATP
pools depletion. However, this treatment was unable to
increase DXR retention in multicellular spheroids but its
effect was evident in monolayers. Since, there is a general
consensus in the literature that P-gp is an energy-driven
pump, where the energy is provided by the hydrolysis of
ATP, our data are puzzle. Nevertheless, using competi-
tions assays, Biswas EE [47], demonstrated that NBD1 of
histidine permease (Hisp) and maltose transporter protein
(Malk), two ABC members, can function as a general
nucleotide binding domain, with a nucleotide preference
CTP>GTP>ATP>>UTP. Thus, the impact of ATP depletion
in DXR retention is not understood for the moment.
In recent years, it has become clear that the multiple non-
P-gp mediated mechanisms may be operational in
tumour spheroids to confer MCR [48]. One mechanism
most recently described is the breast cancer resistance pro-
tein (BCRP), which is a drug pump efflux able to effi-
ciently extrude DXR [49]. Since INER-51 cells express
mRNA for BRCP, we cannot discard the activity of this
protein as a mechanism that helps to maintain lower DXR
retention levels. However, the activity of BCRP as pump
efflux is higher for Rho-123 efflux than DXR, although
their contribution to the drug retention in spheroids is
controversial [50].
In addition to DXR resistance, INER-51 spheroids also
showed resistance to other anticancer drugs such as etopo-
side and methotrexate. Commonly, the etoposide-resist-
ance involves alterations in the nuclear target enzymes
topoisomerases. Oloumi et al[51] indicate that alterations
Table 1: Indices of cytotoxicity (IC50) to several cancer drugs founded in multicellular spheroids and monolayer.
Drug Monolayers IC50 (µM) Multicell. spheroids IC50 (µM)
INER-51 PCS-1 RR INER-51 PCS-1 RR
Doxorubicin 6.2 9.2 1.4 15 9.8 0.6
Etoposide 2.2 4.1 1.8 >50 >50 ----
Methotrexate 0.8 2.8 3.5 >50 >50 ----
Drug exposition was continuous for 72 hours and drug cytotoxicity was performed by MTT assay. IC50: Fifty percent of the decrease in the survival 
rate. RR: The value of relative resistance of INER-51 cells vs PSC-1 cells as monolayers or multicellular spheroids.Cancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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in subcellular localization of topoisomerases type II may
have an important role in resistance to cytotoxic agents
when cells are in a close contact. Whereas Luo et al[52]
showed that phosphorylation of topo II alpha was
reduced at least 10-fold in the outer cells of V79 spheroids
relative to monolayers. However, the role of topoisomer-
ase II alpha as a mechanism to confer MCR to etoposide
in INER-51 spheroids has not been evaluated yet and will
be considered for future experiments.
A different situation can be speculated for the resistance to
methotrexate. Under physiological conditions, the weak
acid methotrexate tends to be in the charged form and is
taken up into cells largely by a folate transport mecha-
nism. Unlike DXR, methotrexate is not sequestered in
membranes nor in acidic endosomes, but it may be
"trapped" inside cells by polyglutamation [53]. Thus, the
differences in methotrexate resistance of INER-51 cells rel-
ative to PSC-1 cells could arise from differences in P-gp-
independent metabolic pathways.
Finally, several reports have shown a lower MDR-1 expres-
sion in NSCLC [54]. However, some authors have shown
an important role of P-gp expression in lung cancer
tumours and particularly in lung cancer diagnosed in peo-
ple whom smoke tobacco [55-57]. Due to our findings, it
would be interesting to evaluate both the levels of P-gp
expression as well as P-gp activity in lung cancer tumours.
Conclusion
Our results suggest that in INER-51 cells cultured as mul-
ticellular spheroids, a more efficient P-gp activity is
responsible for maintaining lower retention levels of DXR
in comparison to the P-gp activity of cells grown as mon-
olayers. Interestingly, whereas the P-gp expression helps
maintain lower levels of DXR in the multicellular sphe-
roids, the mechanisms that govern the MCR seems to be
different because the lack of P-gp-expression only showed
a minor impact of resistance to several chemotherapeutic
drugs, suggesting that other non-P-gp mechanisms are
also operating.
Methods
Chemicals
Doxorubicin (DXR) was provided by Farmitalia-Carlo
Erba, whereas Cyclosporin-A was provided by Sandoz
Farma, whereas SDZ PSC 833 was gift by Novartis. Rhod-
amine-123 (Rho-123) and 3-(4,5-dimethylthiazol-2-yl)-
2,5 diphenyl tetrazolium bromide (MTT) were purchased
from Sigma (St. Luis, MO, USA). All of the working solu-
tions were initially dissolved in dimethyl sulfoxide
(DMSO) and posterior dilutions were put in culture
medium.
Cell lines and culture conditions
The lung cancer cell line INER-51 and its clone PSC-1
(non-expressing P-gp or P-gpneg) were grown as monol-
ayer cultures in RPMI-1640 medium at 37°C in 5% CO2.
INER-51 is a NSCLC cell line established in our laboratory
from pleural effusion of patient diagnosed with primary
lung cancer without previous chemotherapy treatment.
The kidney cell line A498 (expressing P-gp) and the lung
adenocarcinoma cell line INER-37 (expressing MRP1)
were used as controls of P-gp function and MRP1 expres-
sion, respectively. The culture medium was supplemented
with 10% FCS (Sigma, Co. St. Luis, MO, USA), 1% non-
essential amino acids, 1 mM sodium pyruvate, 2 mM L-
glutamine, 100 units/ml of penicillin and 100 µg/ml of
streptomycin.
Culture of monolayers and multicellular spherules
Monolayer cells were passed a week by trypsin-EDTA solu-
tion (Invitrogen™, USA). To obtain multicellular sphe-
roids, 3.5 × 105 exponentially tumour cells were seeded in
1% agarose-coated (24-well/plate) in RPMI-1640 com-
plete medium [14]. Cultures were routinely grown for 72
hours to acquire multicellular spheroids of approximately
of 500 µm of diameter.
P-gp non-expressing mutant clones
In order to obtain one mutant clone with the capacity to
not express P-gp, INER-51 cells were treated as described
by Beketic-Oreskovic, et al[15]. Briefly, 1 × 106 tumour
cells were seeded in a T25  plastic tissue culture flask
(Falcon, USA). When the cell culture achieved a semi-con-
fluent grade, the culture medium was removed and fresh
complete medium was added containing 5 µM DXR and
5 µM of SDZ PSC 833. The cells were maintained under
this condition during two weeks until some survival
clones were evident upon microscopic observation. A
total of 6 survival clones were isolated, propagated for a
month in absence of drugs, and tested for MDR1
expression by in vitro RT-PCR. One mutant clone that
manifested stable for mdr1neg phenotype was selected and
cloned again. Each clone obtained was tested for MDR-1
expression again. Finally, the clone PSC-1 was further
propagated and used for studies in the present
communication.
Drug resistance in monolayers or multicellular spheroids
The level of resistance to drugs was determined with the
use of MTT assay as previously described by S. Cole [16]
and on multicellular systems as evaluated by Furukawa, et
al[17]. For monolayers, 7 × 103 cells/well were plated in
96-well/plate (Costar, USA) and drugs were added in dif-
ferent concentrations per well. In the case of multicellular
spheroids, they were obtained as described above and
were fed with fresh complete medium containing differ-
ent drug concentration. After 72 hours, the cultureCancer Cell International 2005, 5:20 http://www.cancerci.com/content/5/1/20
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medium was retired and MTT reagent diluted in PBS was
added to obtain a final concentration of 2 mg/ml. After
incubation for 4 hours, individual spheroids surrounded
with formazan crystals were transferred into 1.5 ml
eppendorf tubes. Cells in monolayers were washed care-
fully with PBS once. Both monolayers and multicellular
spheroids crystals were dissolved by addition of 100%
DMSO for 20 min with occasional shaking. Absorbance at
540 nm was measured using an automated microplate
reader (Labsystem Multiskan MS, Finland). In each exper-
iment, the drug determination was analysed in six indi-
vidual wells. Cell survival was estimated as a percentage of
the corresponding control. Drug-cytotoxicity was assayed
by the IC50, corresponding to the 50% decrease in cell sur-
vival rate respective to not-drug treated cultures.
Doxorubicin and Rhodamine-123 retention assays
Exponentially growing cells (3.5 × 105) were seeded 72
hours prior to treatment with drugs in 1% agar-coated 24-
well tissue culture plates as described above. Either multi-
cellular spheroids or monolayer cells were incubated with
increased concentrations of DXR or Rho-123 for 30 min
and then washed with fresh drug-free medium twice and
PBS once. Cell suspensions from monolayers were
obtained by tripsinization whereas multicellular
spheroids were recovered using micropipette tips. To
exclude artefacts arising from DXR quenching by binding
to DNA and accumulating in acidic organelles, DXR was
extracted from spheroids with the method described by
Wartenberg et al[18]. Finally, intracellular DXR or Rho-
123 were determined by spectrofluormetry (Phototech-
nology, International, Princeton, New Jersey, USA) at λem
580 nm and λex  427 or λem  510 nm and λex  480
respectively.
Doxorubicin efflux assays
The efflux assays were based on those previously
described [19]. Briefly, monolayers or multicellular sphe-
roids were drug loaded with DXR (30 µM) throughout
incubation at 37°C in 5% CO2 for 30 min. The loading
cells were then washed with a complete drug-free ice-cold
medium and either placed on ice or incubated at 37°C in
5% CO2 for different intervals of time. This incubation
allowed drug efflux to occur, and during experimental
time the remaining drug was quantitated by spec-
trofluormetry as described above.
Circumvention of P-gp-mediated efflux with Cs-A or ATP-
depletion
For evaluation of P-gp activity, monolayers or multicellu-
lar spheroids were pre-incubated for 1 hour with increas-
ing drug concentrations of cyclosporin-A (Cs-A). After
pre-incubation, multicellular spheroids were loaded for
30 min with 30 µM of DXR in presence of the reversal
agent and afterwards the DXR uptake was assessed again.
For ATP-depletion, cells were pre-incubated for 20 min at
4°C in PBS/BSA (1 mg/ml) containing 1 mM sodium-cya-
nide, 10 mM sodium-fluoride and 10 mM sodium azide
prior to the addition of DXR. After centrifugation at 1000
× g for 15 min, both monolayers and multicellular sphe-
roids were loaded with different DXR concentrations in
the presence of ATP synthesis inhibitors and the fluores-
cence was measured as mentioned above.
In vitro Reverse transcriptase-PCR assay
Total RNA was extracted from the cell lines with Trizol rea-
gent (Invitrogen™, USA) according to manufacturer's
instructions. Single stranded cDNA was synthesized by
reverse transcription from 5 µg of total RNA using Super-
script™ RNAse Reverse Transcriptase (Invitrogen™, USA)
and oligo-dT16–18. The amplification was performed in a
final volume of 25 µl, containing 0.5 µl cDNA, 50 pM of
each oligonucleotide primer, 30 µM of each dNTPs, 2.5
units of Taq DNA polymerase, 1.5 mM MgCl2, 20 mM
Tris-HCl (pH 8.4) and 50 mM KCl. Amplification was car-
ried out in a Thermal Cycler (Programmed Thermal Con-
troller, model PTC-100, MJ Research Inc., USA) for 35
cycles of denaturalisation at 94°C for 1 min, annealing at
55–60°C for 2 min, and polymerisation at 72°C for 3
min. The PCR primers and expected product size were as
follows: For MDR-1, forward: 5'-cccatcattgcaatagcagg-3'
and reverse: 5'-gttcaaacttctgctcctga-3 [150 bp]; MRP1, for-
ward: 5'-tctctcccgacatgaccgagg-3' and reverse: 5'-ccag-
gaatatgatgccccgacttc-3' [140 bp]; topoisomerase IIα,
forward: 5'-tttaaggcccaagtccagttaaac-3' and reverse: 5'-
gtataacaatatcatcaagattgt [343 pb]; topoisomerase IIβ,
forward: 5'-gaagtgttcactagtaaaatacagt-3' and reverse: 5'-
cataatctttccatagcgtaaggtt-3' [336 bp]; topoisomerase I, for-
ward: 5'-aagcagaggaagtagctacg-3' and reverse: 5'-gctcatct-
gtttccgagctt-3' [206 bp]; GST-µ, forward: 5'-
gaactccctgaaaagctaaag-3' and reverse: 5'-gttgggct-
caaatatacggtgg-3' [250 bp]; G3PDH, forward: 5'-tggggaag-
gtgaaggtcgga-3' and reverse: 5'-gaaggggtcattgatggcaa-3'
[110 bp].
List of abbreviations
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